{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:17:46Z","timestamp":1785449866845,"version":"3.56.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019999","name":"Geoffrey Beene Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019999","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R01 FD007528"],"award-info":[{"award-number":["R01 FD007528"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The CDK4\/6 inhibitor palbociclib delays progression in patients with advanced dedifferentiated liposarcoma (DDLPS). In carcinoma models, CDK4\/6 and PD-1 inhibition induce intratumoral inflammation and synergistic activity. Comprehensive assessment of tumor and host dynamics is needed to understand response and resistance to this combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>We performed a phase 2 study of palbociclib and the PD-1 inhibitor retifanlimab in advanced DDLPS. Palbociclib was administered 2 weeks prior to retifanlimab. Tumor biopsies were analyzed by single-cell RNA sequencing (scRNA-seq), and peripheral blood by high-parameter flow cytometry. Analyses focused on cell cycle, senescence, and immune-related changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twelve patients were treated before the study was halted because of a 42% immune-related toxicity rate. The overall response rate was 8.3%, and the disease control rate was 75%. Median progression-free and overall survival rates were 7.1 and 26.8 months, respectively. Nine patients had at least one tumor biopsy analyzed; three had paired. Ten patients had paired blood samples analyzed. Following treatment, tumor cells demonstrated decreased cycling and increased cell-cycle checkpoint activity. Transcriptional scores for senescence increased in cancer cells, as did the proportion of intratumoral T and B cells. A cluster of cells emerged with upregulated cell-cycle genes and downregulated HLA class I, suggesting innate or acquired resistance to treatment. In blood, a subset of CD4+ T cells decreased, whereas expression of LAG-3, ICOS, and CD38 increased in select subsets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A palbociclib lead-in prior to retifanlimab had a high rate of immune-related toxicities. Correlative analyses identified changes in tumor and immune cells attributable to treatment. A study of concurrent dosing of the combination is ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In this phase 2 study of palbociclib and retifanlimab, treatment led to immune-related adverse events, halting enrollment. scRNA-seq and flow cytometry revealed cell-cycle suppression, senescence, and T-cell changes. These findings highlight the rationale for this combination and the need for safer dosing strategies in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0334","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T17:42:00Z","timestamp":1764610920000},"page":"437-446","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor and Immune Dynamics Following Sequential CDK4\/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7499-1279","authenticated-orcid":false,"given":"Evan","family":"Rosenbaum","sequence":"first","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4383-2523","authenticated-orcid":false,"given":"Rodrigo","family":"Gularte-M\u00e9rida","sequence":"additional","affiliation":[{"name":"3Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-5548","authenticated-orcid":false,"given":"Evan","family":"Seffar","sequence":"additional","affiliation":[{"name":"3Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4492-4872","authenticated-orcid":false,"given":"Jasme","family":"Lee","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-0126","authenticated-orcid":false,"given":"Mathew","family":"Adamow","sequence":"additional","affiliation":[{"name":"5Immune Monitoring Facility, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-5311","authenticated-orcid":false,"given":"Martina","family":"Bradic","sequence":"additional","affiliation":[{"name":"6Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-751X","authenticated-orcid":false,"given":"Mark A.","family":"Dickson","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2591-7187","authenticated-orcid":false,"given":"Viswatej","family":"Avutu","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-6414","authenticated-orcid":false,"given":"Lauren B.","family":"Banks","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0552-8544","authenticated-orcid":false,"given":"Jason E.","family":"Chan","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0159-5531","authenticated-orcid":false,"given":"Ping","family":"Chi","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8468-0119","authenticated-orcid":false,"given":"Mrinal M.","family":"Gounder","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4393-8088","authenticated-orcid":false,"given":"Ciara M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-4900","authenticated-orcid":false,"given":"Mary Louise","family":"Keohan","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9853-2528","authenticated-orcid":false,"given":"Robert G.","family":"Maki","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-6606","authenticated-orcid":false,"given":"Sujana","family":"Movva","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-2465","authenticated-orcid":false,"given":"Damon R.","family":"Reed","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7607-1521","authenticated-orcid":false,"given":"Rhoena","family":"Desir","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9731-2337","authenticated-orcid":false,"given":"Matthew","family":"Biniakewitz","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1876-727X","authenticated-orcid":false,"given":"Joseph P.","family":"Erinjeri","sequence":"additional","affiliation":[{"name":"8Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3884-9643","authenticated-orcid":false,"given":"Robert A.","family":"Lefkowitz","sequence":"additional","affiliation":[{"name":"8Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-849X","authenticated-orcid":false,"given":"Phillip","family":"Wong","sequence":"additional","affiliation":[{"name":"5Immune Monitoring Facility, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9717-8205","authenticated-orcid":false,"given":"Cristina R.","family":"Antonescu","sequence":"additional","affiliation":[{"name":"9Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9367-3807","authenticated-orcid":false,"given":"Li-Xuan","family":"Qin","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6591-604X","authenticated-orcid":false,"given":"Katherine S.","family":"Panageas","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-584X","authenticated-orcid":false,"given":"Ronglai","family":"Shen","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9713-8230","authenticated-orcid":false,"given":"Samuel","family":"Singer","sequence":"additional","affiliation":[{"name":"3Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-3067","authenticated-orcid":false,"given":"Andrew","family":"Koff","sequence":"additional","affiliation":[{"name":"10Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7779-2796","authenticated-orcid":false,"given":"William D.","family":"Tap","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3736-3783","authenticated-orcid":false,"given":"Sandra P.","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026022704432743700_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/CCO.0b013e32834796e6","article-title":"Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma","volume":"23","author":"Crago","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"2026022704432743700_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.sla.0000086542.11899.38","article-title":"Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma","volume":"238","author":"Singer","year":"2003","journal-title":"Ann Surg"},{"key":"2026022704432743700_bib3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/SLA.0000000000003453","article-title":"Histologic subtype defines the risk and kinetics of recurrence and death for primary extremity\/truncal liposarcoma","volume":"273","author":"Bartlett","year":"2021","journal-title":"Ann Surg"},{"key":"2026022704432743700_bib4","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1200\/JCO.21.01829","article-title":"Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial","volume":"40","author":"Gounder","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026022704432743700_bib5","doi-asserted-by":"crossref","first-page":"11836","DOI":"10.1038\/s41598-017-12132-w","article-title":"Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard","volume":"7","author":"Livingston","year":"2017","journal-title":"Sci Rep"},{"key":"2026022704432743700_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/(SICI)1096-9896(200004)190:5<531::AID-PATH579>3.0.CO;2-W","article-title":"Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours","volume":"190","author":"Dei Tos","year":"2000","journal-title":"J Pathol"},{"issue":"Suppl 15","key":"2026022704432743700_bib7","doi-asserted-by":"crossref","first-page":"11004","DOI":"10.1200\/JCO.2019.37.15_suppl.11004","article-title":"Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma","volume":"37","author":"Dickson","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026022704432743700_bib8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","article-title":"Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial","volume":"2","author":"Dickson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026022704432743700_bib9","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","volume":"31","author":"Dickson","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026022704432743700_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2026022704432743700_bib11","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.18632\/oncotarget.3364","article-title":"MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition","volume":"6","author":"Kovatcheva","year":"2015","journal-title":"Oncotarget"},{"key":"2026022704432743700_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","article-title":"CDK4\/6 inhibitors: the mechanism of action may not be as simple as once thought","volume":"34","author":"Klein","year":"2018","journal-title":"Cancer Cell"},{"key":"2026022704432743700_bib13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/1078-0432.CCR-23-2378","article-title":"Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma","volume":"30","author":"Gleason","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026022704432743700_bib14","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","article-title":"Inhibition of CDK4\/6 promotes CD8 T-cell memory formation","volume":"11","author":"Heckler","year":"2021","journal-title":"Cancer Discov"},{"key":"2026022704432743700_bib15","doi-asserted-by":"crossref","first-page":"e20220729","DOI":"10.1084\/jem.20220729","article-title":"PD-1 blockade and CDK4\/6 inhibition augment nonoverlapping features of T cell activation in cancer","volume":"220","author":"Ali","year":"2023","journal-title":"J Exp Med"},{"key":"2026022704432743700_bib16","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep"},{"key":"2026022704432743700_bib17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"2026022704432743700_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","article-title":"DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors","volume":"8","author":"McGinnis","year":"2019","journal-title":"Cell Syst"},{"key":"2026022704432743700_bib19","doi-asserted-by":"crossref","first-page":"e1009290","DOI":"10.1371\/journal.pcbi.1009290","article-title":"miQC: an adaptive probabilistic framework for quality control of single-cell RNA-sequencing data","volume":"17","author":"Hippen","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"2026022704432743700_bib20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41586-022-04518-2","article-title":"A single-cell atlas of human and mouse white adipose tissue","volume":"603","author":"Emont","year":"2022","journal-title":"Nature"},{"key":"2026022704432743700_bib21","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"2026022704432743700_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2026022704432743700_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13059-021-02451-7","article-title":"Analytic Pearson residuals for normalization of single-cell RNA-seq UMI data","volume":"22","author":"Lause","year":"2021","journal-title":"Genome Biol"},{"key":"2026022704432743700_bib24","doi-asserted-by":"crossref","first-page":"7941","DOI":"10.1038\/s41467-024-52067-1","article-title":"Cellular origin and clonal evolution of human dedifferentiated liposarcoma","volume":"15","author":"Gruel","year":"2024","journal-title":"Nat Commun"},{"key":"2026022704432743700_bib25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat Methods"},{"key":"2026022704432743700_bib26","doi-asserted-by":"crossref","first-page":"100546","DOI":"10.1016\/j.crmeth.2023.100546","article-title":"A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapy","volume":"3","author":"Peng","year":"2023","journal-title":"Cell Rep Methods"},{"key":"2026022704432743700_bib27","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2024"},{"key":"2026022704432743700_bib28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-20-2821","article-title":"Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia\/Ib trial","volume":"27","author":"Patnaik","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026022704432743700_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-022-00273-9","article-title":"Harnessing the immunotherapeutic potential of CDK4\/6 inhibitors in melanoma: is timing everything?","volume":"6","author":"Lelliott","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026022704432743700_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"2026022704432743700_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/eji.201948362","article-title":"CD28 and CD57 define four populations with distinct phenotypic properties within human CD8(+) T cells","volume":"50","author":"Pangrazzi","year":"2020","journal-title":"Eur J Immunol"},{"issue":"Suppl 2","key":"2026022704432743700_bib32","doi-asserted-by":"crossref","first-page":"S1031","DOI":"10.1016\/j.annonc.2024.08.1812","article-title":"1720MO A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma","volume":"35","author":"Rosenbaum","year":"2024","journal-title":"Ann Oncol"},{"key":"2026022704432743700_bib33","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1158\/2159-8290.CD-20-1554","article-title":"CDK4\/6 inhibition promotes antitumor immunity through the induction of T-cell memory","volume":"11","author":"Lelliott","year":"2021","journal-title":"Cancer Discov"},{"key":"2026022704432743700_bib34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0334\/3708446\/crc-25-0334.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/437\/3743466\/crc-25-0334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/437\/3743466\/crc-25-0334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:43:41Z","timestamp":1772185421000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/2\/437\/774902\/Tumor-and-Immune-Dynamics-Following-Sequential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0334","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31429919","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429937","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429939","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429907","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429955","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429911","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429923","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429946","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429925","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429958","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429952","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429931","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429943","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429921","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8329369","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}